Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Breast cancer (BC) is the most common cancer in women worldwide. It is one of the main causes of cancer-related mortality. The breast tumor microenvironment (Br-TME) has emerged as an important factor related to BC development and prognosis. Tumor-associated macrophages (TAMs) are the main effector cells in the Br-TME; they play key roles in regulating angiogenesis, immunosuppression, metastasis, and chemoresistance in BC patients. In this review, we introduce the macrophage niche in the Br-TME, particularly emphasizing the origin of TAMs. Next, we summarize the typical pathways and molecular mechanisms of the interactions between TAMs and various other components in the Br-TME. Finally, we provide an overview of drugs that target TAMs and discuss the prevailing technologies for drug delivery in the context of BC treatment. Identification of the dynamic variations in tumor-promoting TAMs will help reveal the key links that drive BC progression. This review provides a theoretical basis for upcoming clinical trials that may substantially benefit patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12250111 | PMC |
| http://dx.doi.org/10.3390/ijms26135973 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study.
JMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDFHormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.
Cell Mol Biol (Noisy-le-grand)
September 2025
Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.
Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.
View Article and Find Full Text PDFMetastatic breast involvement from extramammary malignancies: a review of dissemination pathways, imaging features, and management strategies.
Radiol Med
September 2025
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.
View Article and Find Full Text PDFUltrasound Video-Based Radiomics Analysis for Differentiating Benign and Malignant Breast Lesions.
Technol Cancer Res Treat
September 2025
Department of Nephrology, Dongyang People's Hospital, Dongyang, China.
ObjectiveTo evaluate the diagnostic performance of a combined model incorporating ultrasound video-based radiomics features and clinical variables for distinguishing between benign and malignant breast lesions.MethodsA total of 346 patients (173 benign and 173 malignant) were retrospectively enrolled. Breast ultrasound videos were acquired and processed using semi-automatic segmentation in 3D Slicer.
View Article and Find Full Text PDFSafety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Asia Pac J Clin Oncol
September 2025
Roche Products India Pvt. Ltd, Mumbai, India.
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.